Home › Research › Topics › flortaucipir-pet
flortaucipir-pet
6 studies tagged flortaucipir-pet, dated 2019-01-01 to 2024-09-19. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions 2024-09-19
- Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET 2021-01-01
- Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study 2020-06-15
Studies
6 studies carry this tag.
Date range
2019 to 2024
Top journals
- Journal of Alzheimer's disease : JAD 2
- Acta neuropathologica 1
- EJNMMI research 1
- European journal of nuclear medicine and molecular imaging 1
- Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
[ 18 F]Flortaucipir is an FDA-approved tau-PET tracer that is increasingly utilized in clinical settings for the diagnosis of Alzheimer's disease.
-
Flortaucipir SUVr values demonstrated significant inverse correlations with cognitive scores in domain-specific patterns.
-
The results of this pilot study support a quantitative relationship between cortical flortaucipir SUVr values and quantitative measures of Ptau at autopsy.
-
Regional [ 18 F]flortaucipir BP ND correlated stronger with cognition and neurodegeneration than CSF p-tau, suggesting that tau PET more accurately reflects disease severity in AD.
-
The aim of this study was to investigate the test-retest (TRT) repeatability of various parametric quantification methods for [ 18 F]Flortaucipir positron emission tomography (PET).
-
At autopsy, individuals with Alzheimer's disease (AD) exhibit heterogeneity in the distribution of neurofibrillary tangles in neocortical and hippocampal regions.